It was reported that the expression of PD-L1, tumor mutation burden (TMB), tumor-specific genes, dMMR/MSI, gut microbiome, and the invasive peripheral blood biomarkers including blood DNA-related biomarkers, blood cell-related biomarkers, and other blood-related biomarkers were potential biomarkers to predict clinical response of anti-PD-1/PD-L1 therapy in cancers (15). This evidence concerns the gene CD274 and neoplasm.